Improved vancomycin dosing in children using area under the curve exposure. - Wikidata - wikimedia - TriplyDB

Improved vancomycin dosing in children using area under the curve exposure.

Improved vancomycin dosing in children using area under the curve exposure.

http://www.wikidata.org/entity/Q36784672

about

Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatrics Pneumococcal Disease in the Era of Pneumococcal Conjugate Vaccine Prospective validation of neonatal vancomycin dosing regimens is urgently needed.Vancomycin monitoring in children using bayesian estimation.Inadequate vancomycin therapy in term and preterm neonates: a retrospective analysis of trough serum concentrations in relation to minimal inhibitory concentrations Vancomycin dosing in healthy-weight, overweight, and obese pediatric patients.Population-Based Pharmacokinetic Modeling of Vancomycin in Children with Renal Insufficiency Association between vancomycin trough concentration and area under the concentration-time curve in neonates Achieving therapeutic vancomycin levels in pediatric patients Validation of a pediatric population pharmacokinetic model for vancomycin.Bayesian Estimation of Vancomycin Pharmacokinetics in Obese Children: Matched Case-Control Study.Evaluation of Target Attainment of Vancomycin Area Under the Curve in Children With Methicillin-Resistant Staphylococcus Aureus Bacteremia.Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?Pediatric Obesity: Pharmacokinetic Alterations and Effects on Antimicrobial Dosing.Pharmacodynamic Characteristics of Nephrotoxicity Associated With Vancomycin Use in Children.Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling.Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates.The effect of age and weight on vancomycin serum trough concentrations in pediatric patients.Are vancomycin trough concentrations adequate for optimal dosing?Vancomycin dosing in children: what is the question?Treating paediatric community-acquired pneumonia in the era of antimicrobial resistance.Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.Factors associated with acute kidney injury in children receiving vancomycin.Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections.Pediatric Assessment of Vancomycin Empiric Dosing (PAVED): a Retrospective Review.Renal Function Descriptors in Neonates: Which Creatinine-Based Formula Best Describes Vancomycin Clearance?Impact of vancomycin protein binding on target attainment in critically ill children: back to the drawing board?Vancomycin Dosing and Pharmacokinetics in Postoperative Pediatric Cardiothoracic Surgery Patients.Optimizing the Use of Antibacterial Agents in the Neonatal Period.Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC/MIC?Assessment of initial vancomycin dosing in neonates Impact of Initial Vancomycin Trough Concentration on Clinical and Microbiological Outcomes of Methicillin-Resistant Staphylococcus aureus Bacteremia in Children Vancomycin AUC/MIC and Corresponding Troughs in a Pediatric Population.Epidemiology of Methicillin-Resistant Staphylococcus aureus Bacteremia in Children.Vancomycin use, dosing and serum trough concentrations in the pediatric population: a retrospective institutional review.AUC-Guided Vancomycin Dosing in Adolescent Patients With Suspected Sepsis.Association of Vancomycin Trough Concentration With Response to Treatment for Acute Pulmonary Exacerbation of Cystic Fibrosis.Are Elevated Vancomycin Serum Trough Concentrations Achieved Within the First 7 Days of Therapy Associated With Acute Kidney Injury in Children?Evaluation of Vancomycin Use in Late-Onset Neonatal Sepsis Using the Area Under the Concentration-Time Curve to the Minimum Inhibitory Concentration ≥400 Target.Risk Factors for Non-Therapeutic Initial Steady-State Vancomycin Trough Concentrations in Children and Adolescents Receiving High Empiric Doses of Intravenous Vancomycin.

P2860

Q26853629-B57CAF28-9476-49F7-9A4F-44F85C0E1F2C Q28088610-6D203BF0-FA90-48DC-A9E2-2CCB14097AA2 Q33906451-E3E24787-0403-4E99-BB9E-07A7DF63AF20 Q33911485-484D29B6-246B-4CE1-A267-EA946D01847B Q34014285-BBB3BD6E-4748-4EBF-8874-3FB9FE6C9B2F Q34297295-80195860-FDB8-4370-97B8-DCD929A9922A Q34314798-58B7C6B6-3370-46CC-B7D4-E69C7C58C34C Q34596435-03C98DCB-3A4D-4EC7-9CEF-3BFB182504F8 Q34764337-B2371F73-0986-444A-8740-77CDB02D8A4E Q35607022-2BBDFBB6-A3B4-4C57-B637-319A0548EEE0 Q35762761-14F4A8EF-F968-470A-8C9F-576830426515 Q36077880-678B67FE-F073-4428-A965-15E2411A7C96 Q36216479-FF5F9A36-09AF-4522-96BB-55A7D583DEC9 Q36247129-E22AAA14-1D8C-4D9A-95E0-07832036C690 Q36377410-6917D121-30F9-4590-9982-68D6DAD03C35 Q36571794-82C14FCF-E81F-478D-96E2-7E25004C52CA Q36684184-3A14F942-8FE4-4985-8430-0189D8DC1FAB Q37347361-9FCF5DBC-F3BA-4967-BD5D-266D2943A206 Q37544400-91C34ACC-F196-4791-8871-F30F2D37FF67 Q38129843-3125FDCC-D6CC-4EB4-BE9F-B81BE49D9B07 Q38170557-F96E16EE-1C8A-45F1-88FB-8F9E931628C9 Q38215682-FABEE1E0-890A-46BE-9929-327FCE27CFDF Q38245931-E892CD34-CF5B-4036-B667-EDCF500ADD22 Q38258649-664602CA-D409-4A49-8D9F-1138A14529C4 Q38392526-D843EBDF-7360-4793-8967-7646D487B3A8 Q38594191-16258099-10E7-486D-B972-DDC4C9F700B5 Q38780026-A02EE29A-C968-4743-8E02-B67FE2DE25C9 Q38784479-07763FB9-9FC2-4378-9580-1219E05F87C9 Q38922653-4A7DAB92-BE0A-4D19-800A-6F5288BE0618 Q39044128-C4A9DD4C-86A9-41C4-AD38-056B08CF5F61 Q39110114-13171E33-A0C9-4911-8B76-B15E200B9624 Q39134281-93DF3C90-6494-4FBA-BED9-911FBDB4D294 Q39197603-879F7300-5300-4F63-A000-2E9D2DBA5E04 Q39340850-059E9D5C-7BB0-4B1B-851D-015B7CF1E89C Q39424620-5909EAF4-0772-4A5B-BF2C-014D4327E8C6 Q39690311-F607B387-FDF2-447E-87E8-EA506ECADE64 Q40048536-98A8C4F0-2C64-4CEF-A5CB-22562D9EA4AD Q40254585-BA47BCB1-DAB1-419D-A7A3-FA8A5C819731 Q40327439-0FD2D332-C74E-4E63-BDEA-ABB26E35BFFA Q40441139-DC3355C3-2915-4018-B89B-DB104F91886B

P2860

Improved vancomycin dosing in children using area under the curve exposure.

http://www.wikidata.org/entity/Q36784672

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Improved vancomycin dosing in children using area under the curve exposure.

@en

type

label

Improved vancomycin dosing in children using area under the curve exposure.

@en

prefLabel

Improved vancomycin dosing in children using area under the curve exposure.

@en

P1433

Q36784672-9E34A302-0859-44D6-9D4D-7DC978A208F0

P1476

Q36784672-9B6916B5-B2F5-4A1E-A23B-3D14432C822A

P2093

Q36784672-1C0175A3-D5AA-41F6-9CBC-61604C4A4619

Q36784672-1C5ED548-DFC2-416C-A6B6-4D5EC110ABBB

Q36784672-4B0435EB-0854-46CB-A96C-A4412B3B2367

Q36784672-5FC8F507-9A2E-41BF-80B8-767D2A0C1AFF

Q36784672-9780ED21-C2E3-4124-87A7-C64D47741862

Q36784672-9D2107F1-B094-4B80-8402-DCD2E1BEBC91

Q36784672-AA9186D4-16E4-43B1-9249-38075732E225

Q36784672-B2A5430C-E602-4AAB-810E-78EC5DE70670

Q36784672-E6B2F75C-809B-4918-8511-89D6E2C126CC

Q36784672-F0361AC1-18A6-48C7-A208-165861DB75DB

P2860

Q36784672-0718060E-F661-477F-B064-6137FB4E038F

Q36784672-1170DAD9-9212-412D-9454-7621A3222A29

Q36784672-238EBA4B-A79F-40A4-93A5-5D9BFB92488F

Q36784672-3B288414-EBE6-41D3-95FE-57E13B6A833F

Q36784672-4476DD75-8C85-4D8C-A666-3E10527EF2DA

Q36784672-545D89B8-9A3E-4F5E-B0AC-CCFC7788E25E

Q36784672-57393DF4-10EA-4C70-88C9-8389EDE8CFD1

Q36784672-5C545479-7876-4114-B273-DD33C9FDC6E1

Q36784672-61D588A4-8E2C-4C86-96D3-EBD20BF1D15A

Q36784672-8305E7E8-3B14-401E-AF95-9EEA6D9E4CA3

P304

Q36784672-3191EE68-2EEA-462C-83B8-73DA8A5BF00C

P31

Q36784672-419CA95B-3D70-459E-B937-34E2DEB23E4E

P356

Q36784672-300D2632-6A6F-4B9C-A788-9E9C0411B14C

P433

Q36784672-311B3342-85DE-420B-BD2F-5173839F404F

P478

Q36784672-74F628A4-0A9D-427F-9F01-14DBBDFCEBE0

P577

Q36784672-E8179FF6-5791-44A1-9174-E9FAE79B14DA

P698

Q36784672-127ABAD5-151A-4594-8C7B-7AC9E030592D

P932

Q36784672-5C8087AD-D9EF-4614-9EBC-41388A5615C9

P356

INF.0B013E318286378E

P1433

Pediatric Infectious Disease Journal

P1476

Improved vancomycin dosing in children using area under the curve exposure.

@en

P2093

Edmund V Capparelli

http://www.w3.org/2001/XMLSchema#string

Gale L Romanowski

http://www.w3.org/2001/XMLSchema#string

Ivilynn Bui

http://www.w3.org/2001/XMLSchema#string

Jennifer Le

http://www.w3.org/2001/XMLSchema#string

John S Bradley

http://www.w3.org/2001/XMLSchema#string

Natalie Nguyen

http://www.w3.org/2001/XMLSchema#string

Stephanie Natale

http://www.w3.org/2001/XMLSchema#string

Susan Cho

http://www.w3.org/2001/XMLSchema#string

Tri M Tran

http://www.w3.org/2001/XMLSchema#string

Tu T Tran

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical characteristics, outcomes, and microbiologic features associated with methicillin-resistant Staphylococcus aureus bacteremia in pediatric patients treated with vancomycin.

Trends in the incidence of methicillin-resistant Staphylococcus aureus infection in children's hospitals in the United States.

A population pharmacokinetic model for vancomycin in pediatric patients and its predictive value in a naive population.

Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.

Therapeutic monitoring of vancomycin according to initial dosing regimen in pediatric patients.

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation

Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate.

Defining risk factors for red man syndrome in children and adults.

An assessment of vancomycin pharmacokinetic variability in pediatric cardiology patients.

P304

e155-63

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/INF.0B013E318286378E

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23340565

http://www.w3.org/2001/XMLSchema#string

P932

3632448

http://www.w3.org/2001/XMLSchema#string